NCT06109779 2026-03-04Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)AstraZenecaPhase 3 Active not recruiting757 enrolled
NCT06591520 2026-01-21AK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract CancerAkesoPhase 3 Active not recruiting682 enrolled
NCT06084481 2026-01-20Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400AbbViePhase 1 Active not recruiting302 enrolled
NCT02628067 2025-09-22KEYNOTE 158Merck Sharp & Dohme LLCPhase 2 Active not recruiting1,609 enrolled 5 FDA
NCT02711553 2025-08-03A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract CancerEli Lilly and CompanyPhase 2 Active not recruiting309 enrolled 22 charts
NCT03440450 2025-05-18A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract CancerFujifilm Pharmaceuticals U.S.A., Inc.Phase 1 Active not recruiting90 enrolled
NCT05506943 2025-04-20A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)Compass TherapeuticsPhase 2/3 Active not recruiting150 enrolled
NCT04660929 2024-12-18CAR-macrophages for the Treatment of HER2 Overexpressing Solid TumorsCarisma Therapeutics IncPhase 1 Active not recruiting48 enrolled